Ghent, 20 October 2026 — 4Tissue, a Belgian medtech company developing solutions for regenerative medicine, announces the successful closing of a €7 million Series A financing round and the appointment of Stéphanie Dupont as Chief Executive Officer (CEO). The financing and leadership appointment mark an important new phase in 4Tissue's development,...
We are proud to announce that 4Tissue has received approval from both the Belgian Federal Agency for Medicines and Health Products (FAMHP/FAGG) and the Ethics Committee (EC) to initiate our First-in-Human (FIH) clinical study.
As the year comes to a close, this is a moment to look back with pride on what we have achieved together. It has been a year filled with challenges, learning curves, and perseverance — and also with progress we can truly be grateful for.
We are thrilled and deeply honored to announce that 4Tissue has been recognized as one of the Top Regenerative Medicine Companies in Europe – 2025 by Life Sciences Review.
At 4Tissue, we're grateful for the opportunity we had to present our innovative breast reconstruction solutions at Knowledge for Growth 2025 in Antwerp.
We're proud to empower women with a groundbreaking breast reconstruction solution that has the potential to tranform the breast cancer recovery journey —helping women regain confidence and strength....
We are thrilled to announce that Dr. Vesna Kostanjevecki has joined 4Tissue as our new Head of Clinical and Regulatory Affairs. As we prepare for the first clinical studies of our innovative hydrogel technology, Dr. Kostanjevecki's appointment is a key step in strengthening our capacity to successfully navigate the regulatory and quality control...
We are thrilled to congratulate An Van Den Bulcke, our co-founder and Chief Business Officer, on her selection for the prestigious EIC Women Leadership Programme, Cohort 8!
For International Women's Day, Invest in Ghent spoke with our very own An Van Den Bulcke and Sandra Van Vlierberghe about the groundbreaking work we're doing at 4Tissue in breast reconstruction using our hydrogel technology.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company's groundbreaking bioresorbable hydrogel...
On the International Day of Women and Girls in Science, we celebrate the groundbreaking contributions of women in science and technology, inspiring future generations to follow in their footsteps. This spirit of empowerment is embodied by us, 4Tissue, a women-led company where leadership, innovation, and progress are driven by women for women.
